A partial responder to atezolizumab harbored TMPRSS2-ERG fusion, MSH2/MHS6 deletion, high TMB (30 mutations/Mb), as well as BRCA2 E49*, TP53 Y236D, AR W742C mutations, and MYC amplification; in this case, PD-L1 positivity was found in ≥5% immune cells and <5% of tumor cells after treatment, while the previous baseline biopsy was negative [19]. This evidence concerns the gene MSH2 and neoplasm.